Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454688
Status:
COMPLETED
Last Update Posted:
2011-10-18
First Post:
2007-03-29
Brief Title:
Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
Sponsor:
Tioga Pharmaceuticals
Organization:
Tioga Pharmaceuticals
Study Overview
Official Title:
A 12-Week Randomized Double-Blind Dose-Ranging Placebo-Controlled Study of Asimadoline in Subjects With Irritable Bowel Syndrome
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of different doses of asimadoline in the treatment of patients with irritable bowel syndrome
Detailed Description:
A randomized dose-ranging double-blind placebo-controlled study designed to evaluate the efficacy and tolerability of three dose levels of asimadoline in subjects with IBS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None